^Original-Research: Cantourage Group SE - from NuWays AG22.12.2025 / 09:00 CET/CESTDissemination of a Research, transmitted by EQS News - a service of EQSGroup.The issuer is solely responsible for the content of this research. Theresult of this research does not constitute investment advice or aninvitation to conclude certain stock exchange transactions.---------------------------------------------------------------------------Classification of NuWays AG to Cantourage Group SE Company Name: Cantourage Group SE ISIN: DE000A3DSV01 Reason for the research: Update Recommendation: BUY from: 22.12.2025 Target price: EUR 10.50 Target price on sight of: 12 months Last rating change: Analyst: Christian SandherrFY25 EBITDA to come in ahead of market estimatesCantourage announced that at the end of November, the company's EBITDAalready stood at EUR5.5m, exceeding the market's expectations of EUR 4.8m (eNuWold: EUR 4.9m) already by roughly10%. Mind you, at the end of Q3, EBITDA stoodat EUR 3.9m as a result of a third quarter with a notablylower profitability.This was the result of price pressure following political uncertainties,whichtriggered industry-wide de-stocking in Germany. In our view, the factthat the first two months of Q4came with a decent margin again, underpinsthat (1) de-stocking has notably decreased and pricesshould be somewhatnormalising and (2) Cantourage is able to weather challengingmarketconditions well thanks to its unique set-up.Our new FY25 estimates now imply a FY EBITDA margin of 6.8% compared to 5.5%previously.Our FY25 sales estimate of EUR 89m remained unchanged.Cantourage to weather potential regulatory changes in Germany well.Cantourage is wellpositioned due to its ability to adapt its product mixtoward higher-margin premium strains, strengthencooperation with offlinepharmacies and actively manage inventories. At the same time, stronggrowthin earlier-stage markets such as the UK and Poland and an improvinggovernance setupsignificantly reduce dependence on Germany and enhanceresilience against regulatory headwinds.Improving corporate governance around the corner. As recently announced, thegroup's newCFO will be starting in January, alongside the five-yearextension of the CEO's contract, whichtogether should notably improveleadership stability, strengthen internal controls and enhance thequalityand timeliness of financial reporting, laying a more robust governancefoundation for futuregrowth. The still pending FY24 consolidated annualreport is expected to be release shortly, eNuW.Valuation remains attractive. Shares continue to trade at a subduedvaluation of 0.4x EV/sales (6xEV/EBITDA) FY25e despite >70% growth improvinggovernance structures and the announcedbetter than expected margins thisyear. Mind you, in September, US-listed High Tide announced the 51%acquisition of Remexian Pharma at an implied EV/sales multiple of 0.84x.Canify, which isrumoured to IPO in 2026, is currently raising money at 2-3xEV/sales (eNuW).We confirm our BUY rating with an unchanged EUR 10.50 PT based on a DCF.You can download the research here:https://eqs-cockpit.com/c/fncls.ssp?u=a89adc096fcfa9f7dc7c808d35ed839bFor additional information visit our website:https://www.nuways-ag.com/research-feedContact for questions:NuWays AG - Equity ResearchWeb: www.nuways-ag.comEmail: research@nuways-ag.comLinkedIn: https://www.linkedin.com/company/nuwaysagAdresse: Mittelweg 16-17, 20148 Hamburg, Germany++++++++++Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschlussbestimmter Börsengeschäfte.Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim obenanalysierten Unternehmen befinden sich in der vollständigen Analyse.++++++++++---------------------------------------------------------------------------The EQS Distribution Services include Regulatory Announcements,Financial/Corporate News and Press Releases.View original content:https://eqs-news.com/?origin_id=9238f568-df08-11f0-be29-0694d9af22cf&lang=en---------------------------------------------------------------------------2249658 22.12.2025 CET/CEST°